283 related articles for article (PubMed ID: 18094431)
1. Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation.
Kobayashi A; Hara H; Ohashi M; Nishimoto T; Yoshida K; Ohkohchi N; Yoshida T; Aoki K
Clin Cancer Res; 2007 Dec; 13(24):7469-79. PubMed ID: 18094431
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
4. In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts.
Narumi K; Udagawa T; Kondoh A; Kobayashi A; Hara H; Ikarashi Y; Ohnami S; Takeshita F; Ochiya T; Okada T; Yamagishi M; Yoshida T; Aoki K
Gene Ther; 2012 Jan; 19(1):34-48. PubMed ID: 21614029
[TBL] [Abstract][Full Text] [Related]
5. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
Cui Y; Kelleher E; Straley E; Fuchs E; Gorski K; Levitsky H; Borrello I; Civin CI; Schoenberger SP; Cheng L; Pardoll DM; Whartenby KA
Nat Med; 2003 Jul; 9(7):952-8. PubMed ID: 12778137
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells.
Luo X; Yu Y; Liang A; Xie Y; Liu S; Guo J; Wang W; Qi R; An H; Zhang M; Xu H; Guo Z; Cao X
Cell Mol Immunol; 2004 Jun; 1(3):199-204. PubMed ID: 16219168
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
13. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor.
He YK; Lui VW; Baar J; Wang L; Shurin M; Almonte C; Watkins SC; Huang L
Gene Ther; 1998 Nov; 5(11):1462-71. PubMed ID: 9930299
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-D-mediated blockade of regulatory T cells within tumors is induced by hematopoietic stem cell transplantation.
Udagawa T; Narumi K; Suzuki K; Aida K; Miyakawa R; Ikarashi Y; Makimoto A; Chikaraishi T; Yoshida T; Aoki K
J Immunol; 2013 Sep; 191(6):3440-52. PubMed ID: 23966628
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.
Fushimi T; O'Connor TP; Crystal RG
Cancer Res; 2006 Apr; 66(7):3513-22. PubMed ID: 16585175
[TBL] [Abstract][Full Text] [Related]
18. Induction of antitumor response by in vivo allogeneic major histocompatibility complex gene transfer using electroporation.
Shimizu H; Nukui Y; Mitsuhashi N; Kimura F; Yoshidome H; Ohtsuka M; Kato A; Miyazaki M
J Surg Res; 2009 Jun; 154(1):60-7. PubMed ID: 19101693
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.
Hamaguchi M; Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Teshima T; Harada M; Yoshikai Y; Naito S
Cancer Sci; 2009 Jan; 100(1):138-43. PubMed ID: 19037994
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
